Pulike Biological Engineering, Inc. (SHA:603566)

SHA:603566 Revenue

Pulike Biological Engineering had revenue of 246.78M CNY in the quarter ending September 30, 2026, a decrease of -6.38%. This brings the company's total for the last twelve months to 1.00B, down -8.96% year-over-year. In the year 2025, Pulike Biological Engineering had annual revenue of 1.09B with 4.54% growth. That makes Pulike Biological Engineering the 19,597th largest company in the world by revenue and 3,594th in China.

• Revenue (ttm): 1.00B
• Revenue Growth: -8.96%
• P/S Ratio: 3.19
• Revenue / Employee: 661.56K
• Employees: 1,519
• Market Cap: 3.21B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Poultry Vaccines and Antibodies 485.23M 45.1%
• Pig Vaccine 263.11M 24.4%
• Chemical 253.71M 23.6%
• Technology Licensing or Transfer Income 27.78M 2.6%
• Functional Health Products, Etc. 24.65M 2.3%
• Pets 16.09M 1.5%
• Vaccines for Ruminants 6.38M 0.6%

By Geography

Chart

• East China 364.75M 33.9%
• Central China 205.37M 19.1%
• Northeast China 129.88M 12.1%
• South China 126.31M 11.7%
• Southwest China 95.93M 8.9%
• North China 95.20M 8.8%
• Northwest China 34.53M 3.2%
• Overseas 24.97M 2.3%

Fiscal year ended Dec 31, 2025 See the full SHA:603566 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.09B	47.32M	4.54%
Dec 31, 2024	1.04B	-210.13M	-16.77%
Dec 31, 2023	1.25B	22.62M	1.84%
Dec 31, 2022	1.23B	131.50M	11.97%
Dec 31, 2021	1.10B	170.06M	18.31%

Data Source: S&P Global Market Intelligence Last updated: Oct 26, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 2, 2026

Data Sources Report a data error